Higher-than-usual doses of radiation in the treatment of inoperable lung cancer can be safely combined with immunotherapy ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Higher-than-usual doses of radiation in the treatment ... safety in selected cases. Lung cancer remains one of the most common and deadliest forms of cancer worldwide. For patients with inoperable ...

“This trial is the first time we’ve ever seen this kind of benefit in treating non-small cell lung cancers caused by KRAS ... asked not to use her last name) saw her cancer return after surgery. After ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – As traditional research institutions ...

The latest data from studies across Bayer's oncology and women's health portfolios will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in ...

It's great to hear about all these advances in the field to provide new options ... Most of our current guidelines are always an extrapolation from lung small cell cancer based guidelines, but the ...

Greetings and welcome to the PDS Biotech first quarter in 2025 earnings conference call. (operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce ...

PDS Biotechnology Corporation (NASDAQ: PDSB) Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation ...